Publikationen in Zusammenarbeit mit Forschern von Hospital Morales Meseguer (20)

2024

  1. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

2021

  1. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

  2. Specific inhalation challenge: The relationship between response, clinical variables and lung function

    Occupational and Environmental Medicine, Vol. 74, Núm. 8, pp. 586-591

2016

  1. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

    Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

  2. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

    Lupus Science and Medicine, Vol. 3, Núm. 1

  3. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

  4. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2015

  1. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

    Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69

2014

  1. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  2. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

  3. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial

    British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336

2013

  1. Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure

    European Journal of Heart Failure, Vol. 15, Núm. 8, pp. 877-884

  2. Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

    Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952

2012

  1. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Blood, Vol. 120, Núm. 13, pp. 2581-2588

  2. Pneumonia treated in the internal medicine department: Focus on healthcare-associated pneumonia

    Clinical Microbiology and Infection, Vol. 18, Núm. 8, pp. 786-794

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941

2007

  1. Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients

    Biology of Blood and Marrow Transplantation, Vol. 13, Núm. 12, pp. 1448-1454

1998

  1. Recomendaciones sobre tratamiento antirretroviral

    Medicina Clinica, Vol. 110, Núm. 3, pp. 109-116

  2. Recomendaciones sobre tratamiento antirretroviral en 1998

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 16, Núm. 8, pp. 374-376